News & Updates

Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.

Ultra-high-dose methylcobalamin (MeCbl) slowed functional decline in individuals with early-stage amyotrophic lateral sclerosis (ALS) with moderate progression, the JETALS* study has shown.

In the treatment of patients with acne vulgaris, the investigational peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) 5% gel appears to help clear lesions and improve acne severity while being safe, according to the results of a phase IIb study.

A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.

Children with overweight or obesity risk developing future type 2 diabetes (T2D) by threefold in the presence of persistent elevations in alanine aminotransferases (ALT), according to a study presented at the 54th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2022).

Treatment with a combination of succinic acid, inosine, nicotinamide, and riboflavin (SINR) is safe and alleviates the symptoms of diabetic polyneuropathy in patients with type 2 diabetes (T2D), according to data from the CYLINDER study.